Regiodivergent Asymmetric Conjugate Addition of 2-Furfuryl Ketones to Nitroalkenes Using Thiourea Organocatalysts
Synlett · 01.12.2025 · 36 (19) · 3245-3249
DOI: 10.1055/a-2648-9222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synlett, erschienen am 01.12.2025. Verfasst von Taro Koda und 7 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
We recently reported the asymmetric ε-regioselective conjugate addition of 2-furfuryl ketones to nitroalkenes utilizing a thiourea–pyrrolidine organocatalyst, resulting in good yields and enantioselectivities. In this study, we present a novel approach for the asymmetric α-regioselective conjugate addition of 2-furfuryl ketones to nitroalkenes using a thiourea–tertiary amine organocatalyst, which has not been previously documented. The reactions produced α-regioselective addition products in high yields and with excellent stereoselectivities. Thus, this work marks the first example of regiodivergent asymmetric conjugate addition of 2-furfuryl ketones to nitroalkenes.
Zitieren
APA
Koda, T., Akutsu, H., Suzuki, M., Nakashima, K., Hirashima, S., Yoshida, A., Miura, T., & Yamanoi, T. (2025). Regiodivergent Asymmetric Conjugate Addition of 2-Furfuryl Ketones to Nitroalkenes Using Thiourea Organocatalysts. Synlett, 36(19), 3245-3249. https://doi.org/10.1055/a-2648-9222
Vancouver
Koda T, Akutsu H, Suzuki M, Nakashima K, Hirashima S, Yoshida A, et al. Regiodivergent Asymmetric Conjugate Addition of 2-Furfuryl Ketones to Nitroalkenes Using Thiourea Organocatalysts. Synlett. 2025;36(19):3245-3249. doi:10.1055/a-2648-9222
BibTeX
@article{Koda2025,
author = {Koda, Taro and Akutsu, Hiroshi and Suzuki, Mitsuaki and Nakashima, Kosuke and Hirashima, Shin-ichi and Yoshida, Akihiro and Miura, Tsuyoshi and Yamanoi, Takashi},
title = {Regiodivergent Asymmetric Conjugate Addition of 2-Furfuryl Ketones to Nitroalkenes Using Thiourea Organocatalysts},
journal = {Synlett},
year = {2025},
volume = {36},
number = {19},
pages = {3245--3249},
doi = {10.1055/a-2648-9222}
}
EUVIMED